The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine - 5 years observation

Hepatology Research

Volumn 27, Issue 1, 2003, Pages 13-17

  Ohkoshi, Shogo ^a   Ogata, Norio ^b   Ichida, Takafumi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chronic hepatitis B; Interferon; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CYTIDINE DERIVATIVE; DNA POLYMERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; RECOMBINANT ALPHA2A INTERFERON; URSODEOXYCHOLIC ACID; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DYSFUNCTION; LONG TERM CARE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; TREATMENT OUTCOME; VIREMIA; VIROLOGY;

EID: 0141828602     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00193-1     Document Type: Article

References (22)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-9.
2. Chang C-N, Doong S-L, Zhou JH, et al. Deoxycitidine deaminase-resistant stereoisomer is the active form of (+/-)-2′, 3′ dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992;267:13938-42.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
4. Lai C, Chien R, Leung N, et al. A one year trial of lamivudine for chronic hepatitis B infection. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
5. Dienstag J, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
6. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
7. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during the therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
8. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
9. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
10. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998;28:510-3.
11. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
12. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1990;30:567-72.
13. Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001;121:1027-8.
14. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5.
15. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-6.
16. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site(YMDD) motif. Hepatol Res 2000;17:31-42.
17. Someya T, Suzuki Y, Arase Y, et al. Interferon therapy for flare-up of hepatitis B virus infection after the emergence of lamivudine-induced YMDD motif mutant. J Gastroenterol 2001;36:133-6.
18. Liaw Y-F. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002(Suppl. 3):S333-7.
19. Liaw Y-F, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
20. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
21. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone. Hepatology 2001;34:573-7.
22. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged LMV therapy. Hepatology 2001;34:785-91.